TriangleBiospecimen Collection (NCT06571734)
Biospecimen Collection trial for Metastatic Leiomyosarcoma (NCT06571734). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic or unresectable leiomyosarcoma after at least two treatments, or bone sarcoma or translocation-associated soft-tissue sarcoma after at least one. No more than two previous kinase-inhibitor treatments are allowed.
The idea: daily oral zanzalintinib blocks growth-related signals between cells. Treatment repeats in fourteen-day cycles while tolerated without progression. Researchers assess six-month disease control, response, survival and toxicity. Participants have blood tests, CT scans and heart-function assessment. Prior zanzalintinib excludes entry.
This phase 2 study plans 73 patients. Pedro Hermida de Viveiros leads Northwestern’s recruiting Chicago site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.